SM 10906

Drug Profile

SM 10906

Alternative Names: SM-10906

Latest Information Update: 30 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Pharmaceuticals
  • Class Antiplatelets
  • Mechanism of Action Collagenase stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Blood coagulation disorders; Hypertrophic scars

Most Recent Events

  • 07 Jan 2004 No development reported - Preclinical for Coagulation disorders in Japan (unspecified route)
  • 28 Jun 2001 No-Development-Reported for Hypertrophic scars in Japan (Unknown route)
  • 19 Jan 1998 Preclinical development for Hypertrophic scars in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top